NEW YORK, Dec. 11, 2021 /PRNewswire/ -- Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology, today presented preclinical data that support the potential ...
The data presented today demonstrate the potency and anti-tumor activity of ISB 1442 in multiple in vitro and in vivo tumor models relative to daratumumab and magrolimab. Specifically, the results ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results